SenesTech Aktie Logo
US81720R5054
A3EVGZ
SNES

SenesTech Aktie

Caricamento quotazioni...

Previsioni

Acquista
  2
Mantieni
  0
Vendi
  0

  • SenesTech reports record figures and accelerated turnaround after realignment

    At the Lytham Partners Summit, SenesTech presented an operational realignment completed in about 200 days that led to record revenues, record gross profits and improved margins for the quarter. E‑commerce revenues nearly tripled, subscription revenues nearly doubled, and the company reduced monthly cash burn, bringing cash‑flow breakeven into view. Management is building two growth engines — a restructured e‑commerce business and a structured B2B sales organization — and sees scaling potential without substantial additional investment. » Altro su de.investing.com


  • SenesTech launches distribution of Evolve birth control in Bermuda

    SenesTech has signed a distribution agreement with Animal and Garden House to introduce its Evolve rodent birth-control product in Bermuda. The product aims to reduce rodent populations through fertility control instead of lethal rodenticides and can supplement or replace existing pest-control programs. The expansion, CEO Michael Edell said, aligns with Bermuda’s environmental protection focus; the company is already active in the U.S. Virgin Islands and Belize. SenesTech most recently reported a market capitalization of $8.16 million, annual revenue of $2.23 million and growth of 15.67%, while analysts note undervaluation and increased cash burn associated with the expansion. » Altro su de.investing.com


  • SenesTech increases Q1 revenue slightly to $493,000, gross margin reaches record

    SenesTech reported a 2% revenue increase in the first quarter of 2026 to $493,000 and a record gross margin of 68.6%. Direct management of the Amazon account led to a 42% rise in D2C revenue; subscription revenues grew 44%. Management sees long-term benefits from the sales shift and expansion of the subscription model, but warned of short-term revenue disruptions. The stock fell about 4% in premarket trading. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, SenesTech Aktie ha registrato ricavi pari a 674,68K € e un utile netto di -1,61 Mln €
(EUR) giu 2026
YoY
Ricavi 674,68K 27,24%
Utile lordo 496,81K 43,17%
Utile netto -1,61 Mln 17,08%
EBITDA -1,57 Mln 17,77%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
5,04 Mln €
Numero di azioni
5,3 Mln
Massimo/minimo a 52 settimane
4,62 € - 0,91 €
Dividendi No
Beta
0,26
Rapporto P/E
-0,80
Rapporto PEG
0,00
Rapporto P/B
0,96
Rapporto P/S
2,46

Profilo aziendale

SenesTech, Inc. entwickelt eine Technologie zur Kontrolle von Tierschädlingspopulationen durch Fruchtbarkeitskontrolle. Es bietet ContraPest an, einen Flüssigköder, der die Fortpflanzung von männlichen und weiblichen Ratten einschränkt. Das Unternehmen wurde im Jahr 2004 gegründet und hat seinen Hauptsitz in Phoenix, Arizona.

Nome
SenesTech Aktie
CEO
Michael Edell
Sede centrale Surprise, az
Stati Uniti
Sito web
Industria
Prodotti chimici
Quotazione in borsa
08/12/2016
Dipendenti 24

Simboli di borsa

Borsa Simbolo
NASDAQ
SNES
Frankfurt
SE81.F
🍪

Parqet  usa i cookie. Scopri di più